Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion, Bio-Rad Settle Claims Stemming from Sale of Proteomics Technology

NEW YORK (GenomeWeb News) – Vermillion today announced that all four non-contingent contract claims with Bio-Rad Laboratories stemming from Vermillion's sale of its proteomics business in 2006 have been settled.

Following Vermillion's Chapter 11 bankruptcy filing in 2009, Bio-Rad filed a proof of claim for about $1 million based on the four non-contingent contract claims.

As part of today's announced settlement, Vermillion will pay $700,000 to Bio-Rad from an escrow account established by Vermillion for the sale transaction, while Vermillion will be returned a little more than $1 million from the escrow account. Another $50,000 will remain in escrow as security for Bio-Rad's contingent indemnity claim related to a lawsuit involving Molecular Analytical Systems, the former parent firm of Vermillion, once called Ciphergen.

When Vermillion sold its SELDI technology to Bio-Rad in 2006, MAS sued Vermillion alleging breach of a licensing agreement. MAS claims it had to sign off on the terms of Bio-Rad deal, GenomeWeb Daily News' sister publication ProteoMonitor reported at the time.

"Given that it returns to us the majority of the $1.8 million remaining in the escrow account, we view this resolution with Bio-Rad as very successful," Gail Page, president and CEO of Vermillion, said in a statement, adding that the company will now focus its attention on accelerating the commercialization of its OVA1 ovarian cancer triage test and advancing its product pipeline.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.